Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase ◽

Egfr Antibody

The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers

Journal of Biological Chemistry ◽

10.1074/jbc.m605136200 ◽

2006 ◽

Vol 282 (5) ◽

pp. 2840-2850 ◽

Cited By ~ 74

Author(s):

Hui K. Gan ◽

Francesca Walker ◽

Antony W. Burgess ◽

Angela Rigopoulos ◽

Andrew M. Scott ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Egfr Tyrosine Kinase ◽

Epidermal Growth

Abstract 1158: Multiple molecular targeting effects by miR-7 in EGFR tyrosine kinase inhibitor-resistant lung cancer xenograft models

10.1158/1538-7445.am2011-1158 ◽

2011 ◽

Author(s):

Kammei Rai ◽

Nagio Takigawa ◽

Sachio Ito ◽

Katsuyuki Kiura ◽

Tateji Yasuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase ◽

Xenograft Models

346 The EGFR tyrosine kinase inhibitor erlotinib induces cell cycle arrest and apoptosis in human hepatocellular cancer cells and enhances chemosensitivity to doxorubicin, docetaxel, and SN-38

Journal of Hepatology ◽

10.1016/s0168-8278(05)81758-1 ◽

2005 ◽

Vol 42 ◽

pp. 128

Keyword(s):

Cell Cycle ◽

Tyrosine Kinase ◽

Cell Cycle Arrest ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Egfr Tyrosine Kinase ◽

Cycle Arrest

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Egfr Tki

O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)

Lung Cancer ◽

10.1016/s0169-5002(03)91905-2 ◽

2003 ◽

Vol 41 ◽

pp. S72 ◽

Cited By ~ 6

Author(s):

Roman Perez-Soler ◽

Qun Dai ◽

Yi-He Ling ◽

Marie Lee ◽

Glenn Kroog ◽

...

Keyword(s):

Tyrosine Kinase ◽

Molecular Mechanisms ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Cited By ~ 113

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Line Treatment ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Oncology Letters ◽

10.3892/ol.2019.10942 ◽

2019 ◽

Author(s):

Ching‑Hu Chung

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Tyrosine Kinase ◽

Clinical Outcomes ◽

Kinase Inhibitor ◽

Cancer Treatments ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Oncogene ◽

10.1038/s41388-018-0517-4 ◽

2018 ◽

Vol 38 (9) ◽

pp. 1398-1409 ◽

Cited By ~ 15

Author(s):

Kimio Yonesaka ◽

Naoki Takegawa ◽

Satomi Watanabe ◽

Koji Haratani ◽

Hisato Kawakami ◽

...

Keyword(s):

Tyrosine Kinase ◽

Topoisomerase I ◽

Kinase Inhibitor ◽

Dna Topoisomerase I ◽

Antibody Drug Conjugate ◽

Dna Topoisomerase ◽

Egfr Tyrosine Kinase ◽

Antibody Drug